CNTN1 and nephrotic syndrome: PLA2R antibody testing was performed where possible, and found to be negative in these four, and 10/15 patients with CNTN1 antibodies, nephrotic syndrome and a neuropathy (14/19 in total)—the remaining sera unavailable for further testing.